Antazoline: the Lazarus of antiarrhythmic drugs?

Pol Arch Intern Med. 2022 Jun 29;132(6):16264. doi: 10.20452/pamw.16264. Epub 2022 Jun 29.

Authors

Peter Calvert¹, Dhiraj Gupta¹, Gregory Y H Lip²

Affiliations

¹ Liverpool Center for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
² Liverpool Center for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. gregory.lip@liverpool.ac.uk

PMID: 35766936
DOI: 10.20452/pamw.16264

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antazoline*
Anti-Arrhythmia Agents / adverse effects
Atrial Fibrillation* / drug therapy
Humans

Substances

Anti-Arrhythmia Agents
Antazoline